MarketVIEW Maternal & Viral Infectious Disease Vaccines  ·  April 2022 edition, Q4 2023 modifications

Congenital Cytomegalovirus (CMV)
Vaccines Commercial Forecast

Congenital cytomegalovirus is the most common infectious cause of birth defects and childhood disability in the world, and a vaccine to prevent it has been pursued for more than four decades. In 2025 the most advanced candidate in history, Moderna's mRNA-1647, missed its primary endpoint in the largest CMV vaccine trial ever run, a genuine reset for the field. This is the independent commercial assessment of what comes next, drawing on VacZine Analytics' long-standing, independent authority in viral infectious disease vaccine markets.

Leading Candidate Missed Phase 3 (2025) 1 in 200 US Births Affected 25 Major Markets to 2040 Maternal & Transplant Indications
Product catalogue
VAMV014
April 2022 edition, Q4 2023 modifications

Format
PDF (>175 slides) + Excel
Coverage
25 major Western & ROW markets
Vaccines assessed
mRNA-1647, V160, GSK
Markets
Public & private
Approach
Scenario-based
Horizon
To 2040
Availability
Syndicated / bespoke
1 in 200
US births affected by
congenital CMV each year
~8,000
US infants a year left with
lasting neurological sequelae
25%
Of childhood deafness
attributable to congenital CMV
2025
Year the leading Phase 3
candidate missed its endpoint
Disease background

Why congenital CMV has remained a vaccine priority for four decades

Cytomegalovirus is a near-universal, usually silent infection in adults, but its transmission from mother to child makes it the leading infectious cause of birth defects and childhood disability worldwide. Understanding that burden, and why the field's most advanced candidate has just fallen short, is central to understanding what a workable vaccine could still be worth.

Peer-reviewed & 2026 pipeline data

Pathogen overview - Human cytomegalovirus (CMV)

Cytomegalovirus is a DNA virus and member of the herpesvirus family (Betaherpesvirinae), and one of the most widely prevalent pathogens in humans. In the United States, an estimated 50 to 80% of adults are infected by 40 years of age (US CDC), while in developing regions seroprevalence is materially higher and acquired at younger ages. Following primary infection the virus establishes lifelong latency; in immunocompetent individuals this usually causes no significant health issues, but in those with a weakened immune system, HIV-positive individuals, and haematopoietic stem cell or solid organ transplant recipients, the virus can reactivate and cause severe disease, notably pneumonia and other end-organ disease.

CMV's greatest public-health significance, however, lies in mother-to-child transmission. Congenital CMV (cCMV) follows transmission from a pregnant woman to her fetus before or after birth, and it is now recognised as the most common congenital infection worldwide. Pooled global birth prevalence is estimated at approximately 0.67%, though this varies markedly by setting: prevalence is roughly threefold higher in lower- and middle-income countries (around 1.42%) than in high-income countries (around 0.48%). In the United States alone, an estimated 20,000 to 40,000 infants, around 1 in 200 births, are born with cCMV each year.

Up to one in five infants born with cCMV is symptomatic at birth, and around 8,000 US infants annually go on to develop lasting neurological sequelae: sensorineural hearing loss, intellectual disability, psychomotor delay, and speech and language disabilities. Congenital CMV is estimated to account for roughly 10% of childhood cerebral palsy and up to 25% of childhood deafness, and is an under-recognised contributor to miscarriage, stillbirth and preterm birth. Taken together, CMV is the leading infectious cause of birth defects and childhood disability, a burden that has driven vaccine developers for more than four decades.

That pursuit met a hard reset in 2025. Moderna's mRNA-1647, evaluated in the largest CMV vaccine trial ever conducted (CMVictory, approximately 7,500 CMV-seronegative women aged 16 to 40 across 13 countries), missed its primary efficacy endpoint, showing only 6 to 23% efficacy against infection depending on case definition, well short of what would support licensure. Moderna has discontinued the congenital-prevention programme, though it continues to evaluate mRNA-1647 in transplant recipients, a related but commercially distinct indication. The field's remaining hopes now rest on Merck's V160 (an inconclusive Phase 2b readout in 2023) and GSK's earlier-stage gB/pentamer subunit candidate.

2026 1 in 200 US births affected  |  ~8,000 US infants a year with lasting sequelae  |  up to 25% of childhood deafness  |  leading candidate missed Phase 3
Product & competitor landscape

Four decades of pursuit - and a leading candidate's Phase 3 miss

Congenital CMV vaccine development has been a priority since the 1970s. In 2025 the most advanced candidate in history fell well short in its pivotal trial, a genuine reset for the field that changes near-term commercial expectations without eliminating the underlying opportunity.

  • ModernaPhase 3 missed, 2025
    mRNA-1647 Discontinued for cCMV
    The most advanced congenital CMV vaccine candidate in history and the first to reach Phase 3. The CMVictory trial, the largest CMV vaccine study ever conducted (~7,500 CMV-seronegative women aged 16 to 40, 13 countries), missed its primary efficacy endpoint, showing only 6 to 23% efficacy depending on case definition. Moderna has discontinued the congenital-prevention programme but continues to evaluate mRNA-1647 in haematopoietic stem cell and solid organ transplant recipients, where CMV reactivation, not primary infection, is the target.
  • Merck & CoPhase 2b, inconclusive
    V160
    A conditionally replication-defective whole-virus vaccine restoring the pentameric complex (gH/gL/pUL128-131) alongside gB and tegument antigens. A randomised, placebo-controlled Phase 2b trial in CMV-seronegative women (published 2023) showed 42.4% efficacy in a three-dose regimen, a signal that did not reach statistical significance, while the two-dose regimen showed no protective effect. No Phase 3 advancement has been announced.
  • GSKEarlier stage
    gB / pentamer subunit candidate
    A recombinant protein subunit vaccine combining glycoprotein B (gB) and the pentameric complex, designed to improve on the partial protection shown by earlier gB-only approaches. Positioned as a second-generation subunit strategy behind the more clinically advanced mRNA and whole-virus candidates.
  • Historical benchmarkNever licensed
    gB/MF59 subunit vaccine (academic)
    The MF59-adjuvanted Towne-strain gB subunit vaccine remains, more than two decades on, one of the only CMV vaccine candidates to show a clear efficacy signal in randomised trials, around 50% protection in several Phase 2 studies. It was never advanced to licensure but continues to inform antigen-design decisions across the current pipeline, including GSK's combination approach.
  • Second-wave & non-vaccine approachesVarious
    Earlier-stage candidates and hygiene-based prevention
    Earlier-stage academic and biotech nanoparticle and vector-based candidates continue in development, alongside renewed public-health emphasis on hygiene-based prevention counselling for seronegative pregnant women, a lower-cost intervention now attracting fresh attention following the CMVictory result.
Market reset
2025

Moderna's CMVictory result is the defining commercial event in this market. The most advanced congenital CMV vaccine candidate in history, tested in the largest trial the field has ever run, fell well short of the efficacy needed for licensure. That does not eliminate the underlying opportunity, cCMV remains the leading infectious cause of childhood disability worldwide, but it resets timelines, derisks no single asset, and raises the bar for every remaining candidate. The VacZine Analytics model quantifies the commercial opportunity under multiple pipeline-recovery scenarios.

Scope of analysis

Six analytical layers - one commercial picture

The MarketVIEW congenital CMV analysis spans disease burden, target-population rationale, the post-CMVictory competitor landscape and scenario-based revenue forecasting across 25 major Western and emerging markets to 2040.

Patient forecast across 25 markets

Bottom-up modelling across 25 major Western and emerging markets, tracking maternal vaccination strategies by target population and CMV serostatus, to 2040.

Competitor & pipeline review

mRNA-1647's Phase 3 miss, Merck V160's inconclusive Phase 2b data, and GSK's earlier subunit candidate, with realistic efficacy-endpoint assumptions informed by CMVictory.

Serostatus-based scenario modelling

Vaccinee CMV serostatus, targeting strategy (universal adolescent, pre-conception or pregnancy-based) and coverage-benchmark scenarios.

Scenario-based revenue forecasts

Base, upside and conservative scenarios across public and private markets, with explicit assumptions reflecting the post-2025 pipeline reset.

Disease burden & epidemiology

Updated global and regional cCMV birth prevalence, neurological sequelae burden, and childhood deafness and cerebral palsy attribution.

Regulatory pathway & CE modelling

Review of regulatory paths to licensure and the latest mathematical and cost-effectiveness modelling studies informing pricing and access.

Sample analysis

A glimpse of the commercial model

The table below shows a partial view of the target-population and scenario framework. Full revenue outputs, pricing assumptions and country-level data are in the licensed model.

Target populationGeographyMarket typeVaccine profileRevenue scenario
Seronegative women (16 to 40)US + EU5Public + privatemRNA / subunitModelled
Adolescent universal cohort25-marketPublic programmeUniversal scheduleModelled
Transplant recipients (HSCT/SOT)GlobalHospital / institutionalReactivation preventionModelled
█████████████████████████$██m (base)
█████████████████████████$██m (upside)
Total addressable - baseGlobalAllAll profiles$███m
Full model in the licensed workbook
25 markets · serostatus · targeting strategy · pricing detail
Register interest →
Deliverables

What you receive

A comprehensive intelligence package combining a detailed executive presentation and a fully interactive forecast model, built for decision-makers who need the full picture on the congenital CMV vaccine opportunity.

  • Executive presentation (>175 slides, PDF) - disease background, epidemiology, the CMVictory Phase 3 result, competitor programmes, regulatory pathway review and full commercial assessment with supporting narrative and references
  • Interactive MS-Excel forecast model - volume and revenue outputs across 25 major Western and emerging markets to 2040, with toggles for target population, serostatus, price, coverage and launch sequence
  • Scenario-based commercial forecasts - base, upside and conservative cases reflecting pipeline-recovery scenarios after the 2025 reset
  • Competitor intelligence - mRNA-1647, V160 and GSK's subunit candidate, benchmarked against the historical gB/MF59 efficacy signal
  • Updated epidemiology module - global and regional cCMV birth prevalence, neurological sequelae, and childhood deafness and cerebral palsy attribution
  • Regulatory & cost-effectiveness review - paths to licensure and the latest mathematical and cost-effectiveness modelling studies
Target audience

Built for organisations weighing the CMV opportunity

Most valuable to teams evaluating the congenital CMV vaccine market against their own pipeline, BD ambitions or investment thesis, particularly in light of the 2025 CMVictory result and what it means for the assets left standing.

Vaccine developers

Positioning, commercial feasibility and target-population prioritisation for CMV candidates at any stage.

Corporate strategy & BD

Validate the market size and structure after the CMVictory reset, and understand what it means for the remaining pipeline.

Investors & analysts

Independent assessment of market size and pipeline risk for due diligence on CMV and adjacent maternal/viral vaccine assets.

Public health & maternal programmes

Demand modelling for maternal and adolescent immunisation programmes and hygiene-based prevention strategies.

Researchers & academia

Comprehensive epidemiology and the vaccine landscape for grant and translational planning, including the CMVictory data.

Market access & policy

Regulatory pathway and cost-effectiveness benchmarks to inform pricing and reimbursement planning.

About this analysis · VAMV014

VacZine Analytics has tracked viral infectious disease vaccine markets since our earliest editions, positioning us to reassess congenital CMV the moment the pipeline changed. This analysis combines a rigorous epidemiological and clinical review with an independently constructed commercial model spanning 25 major Western and emerging markets that most forecasts model only in aggregate. Few groups have followed this market as closely or for as long, and that recognised, independent expertise underpins everything in the analysis.

This report was last fully published in April 2022, with modifications added in Q4 2023. A full refresh, incorporating the 2025 CMVictory Phase 3 result and reassessing the remaining pipeline, is available on syndicated or bespoke terms. The syndicated route proceeds subject to sufficient client buy-in; where a faster or more tailored answer is required, VacZine Analytics can also be commissioned to deliver bespoke, ad-hoc analysis on this market.

MarketVIEW · VAMV014 · Syndicated & bespoke

Syndicate the refresh - or commission the answer you need

Register your interest to help shape and secure a full syndicated MarketVIEW refresh, which proceeds subject to sufficient client buy-in. Single-licence and multi-user options follow on publication. Need something faster or more specific? VacZine Analytics can be commissioned for bespoke, ad-hoc CMV analysis, a briefing call is included on request.